Abstract
In dialysis therapy, high-flux dialysis membrane has improved the ability to remove uremic toxins (not only small water-soluble molecules but also middle molecules). Thus, with increasing permeability of the dialysis membrane to water, hemodiafiltration with high-volume replacement fluid has become available.
The increased permeability of the dialysis membrane to solutes and water enhances backfiltration and back diffusion from dialysate to blood. If the dialysate is contaminated, the pyrogen enters into the blood and can cause microinflammation. Therefore, dialysate purification is essential for strict management.
There is no clear evidence whether the high-flux dialysis membrane contributes to improve survival of dialysis patients. Future studies are required to clarify this issue.
This is a preview of subscription content, log in via an institution to check access.
References
Fournier A, Birmelé B, François M, Prat L, Halimi J-M. Factors associated with albumin loss in post-dilution hemodiafiltration and nutritional consequences. Int J Artif Organs. 2015;38(2):75–82.
Gejyo F, Homma N, Suzuki Y, Arakawa M. Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med. 1986;314(9):585–6.
Kawanishi H, Akiba T, Masakane I, Tomo T, Mineshima M, Kawasaki T, Hirakata H, Akizawa T. Standard on Microbiological Management of Fluids for Hemodialysis and Related Therapies by the Japanese Society for Dialysis Therapy 2008. Ther Apher Dial. 2009;13(2):161–6.
Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S. Claudio Ronco, and Raymond Vanholder, for the membrane permeability outcome (MPO) study group effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20:645–54.
Masakane I. Regular dialysis treatment in Japan as of Dec. 31.2014, Japanese society for Dialysis therapy(in Japanese). Toseki Igakkai Zasshi. 2016;49(1):1–34.
Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, Kimata N, Shigematsu T, Shinoda T, Syouji T, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Marubayashi S, Morita O, Yamagata K, Wakai K, Watanabe Y, Iseki K, Tsubakihara Y. Regular dialysis treatment in Japan as of Dec. 31.2008, Japanese society for Dialysis therapy(in Japanese). Ther Apher Dial. 2010;14(6):505–40.
Palmer SC, Rabindranath KS, Craig JC, Roderick PJ, Locatelli F, Strippoli GF. High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database Syst Rev. 2012;9:CD005016. https://doi.org/10.1002/14651858.CD005016.pub2.
Vanholder R, Van Laecke S, Glorieux G. What is new in uremic toxicity? Pediatr Nephrol. 2008;23:1211–21.
Yokoyama H, Kawaguchi T, Wada T, Takahashi Y, Higashi T, Yamazaki S, Fukuhara S, Akiba T, Akizawa T, Asano Y, Kurokawa K, Saito A, J-DOPPS Research Group. Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in japanese patients on chronic non-reuse hemodialysis: a prospective cohort study from the J-DOPPS II study. Nephron Clin Pract. 2008;109(2):100–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Tomo, T. (2018). Flux of Dialysis Membrane: Benefit and Risk. In: Kim, YL., Kawanishi, H. (eds) The Essentials of Clinical Dialysis. Springer, Singapore. https://doi.org/10.1007/978-981-10-1100-9_6
Download citation
DOI: https://doi.org/10.1007/978-981-10-1100-9_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-1099-6
Online ISBN: 978-981-10-1100-9
eBook Packages: MedicineMedicine (R0)